ADMA Biologics, Inc., a biopharmaceutical company headquartered in Ramsey, United States, has been making significant strides in the health care sector, particularly within the biotechnology industry. The company is primarily listed on the Nasdaq exchange and operates with the United States Dollar (USD) as its currency. As of October 15, 2026, ADMA Biologics’ stock closed at $10.68, reflecting a notable fluctuation over the past year. The company’s stock reached a 52-week high of $20.458 on December 11, 2025, and a 52-week low of $7.21 on March 25, 2026.
With a market capitalization of approximately $2.39 billion, ADMA Biologics has established itself as a significant player in the biotechnology field. The company’s focus is on developing and commercializing human plasma and plasma-derived therapeutics, targeting immunity-compromised patients. This specialization underscores its commitment to addressing critical health care needs through innovative biopharmaceutical solutions.
The company’s financial metrics, including a price-to-earnings ratio of 15.34, indicate a balanced valuation in the context of its industry peers. This ratio reflects investor confidence in ADMA Biologics’ growth potential and its strategic initiatives in the biopharmaceutical landscape.
ADMA Biologics’ dedication to advancing plasma-derived therapeutics is pivotal in its mission to enhance patient care for those with compromised immune systems. By leveraging cutting-edge biotechnology, the company aims to expand its therapeutic offerings and solidify its position in the global health care market.
As ADMA Biologics continues to navigate the dynamic biotechnology sector, its strategic focus on innovation and patient-centric solutions remains central to its operational ethos. The company’s ongoing efforts to develop new therapies and expand its market presence are likely to influence its future trajectory in the health care industry.
